RxDoctor Payments DataLook up a doctor →

Mohammad Taher, MD

Neurology · American Fork, UTNPI 1992762918

Payments from drug & device makers

$44,708in general payments, 2019–2025

Across 901 payments — averaging $49.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Biohaven Pharmaceuticals, Inc.$11K
  • Novartis$1K
  • Biogen$1K
  • Neurocrine Biosciences, Inc.$871
  • Sanofi$849
  • plus $11K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)189$18,798
Biohaven Pharmaceuticals, Inc.17$10,950
Novartis75$1,076
Biogen47$1,005
Neurocrine Biosciences, Inc.43$871
Sanofi39$849
UCB, Inc.27$703
Amneal Pharmaceuticals LLC33$663
EMD Serono, Inc.40$643
MDD US Operations, LLC14$593
Argenx US, Inc.20$563
Livanova USA, Inc.13$562
SK Life Science, Inc.20$557
Lilly USA, LLC32$550
Acadia Pharmaceuticals Inc29$511
Teva Pharmaceuticals USA, Inc.22$412
Jazz Pharmaceuticals Inc.12$403
Genentech USA, Inc.21$397
Bristol Myers Squibb20$338
Harmony Biosciences LLC12$337
Lundbeck LLC17$314
Amgen(2 entities)12$280
Johnson & Johnson8$268
Pfizer14$266
Sunovion Pharmaceuticals Inc.13$261
Neurelis, Inc.12$257
Greenwich Biosciences, Inc.11$232
E.r. Squibb & Sons, L.L.C.7$207
Abbott6$194
Axsome Therapeutics, Inc.6$168
AstraZeneca8$166
Adamas Pharmaceuticals, Inc.7$137
Supernus Pharmaceuticals, Inc.8$123
Acorda Therapeutics, Inc5$106
Genentech, Inc.2$96
Merz Pharmaceuticals, LLC3$85
Takeda Pharmaceuticals U.S.A., Inc.4$83
Eisai Inc.4$82
Biohaven Pharmaceutical Holding Company Ltd.4$77
ANI Pharmaceuticals, Inc.3$73
Tanabe Pharma America, Inc.3$63
Vanda Pharmaceuticals Inc.2$56
Impel Pharmaceuticals Inc.3$56
Boston Scientific2$53
Corium, LLC3$37
GE HealthCare1$34
Alnylam Pharmaceuticals Inc.1$30
TG Therapeutics, Inc.1$28
Kedrion Biopharma, Inc.1$22
Catalyst Pharmaceuticals, Inc.1$21
Banner Life Sciences, LLC1$15
Azurity Pharmaceuticals, Inc.1$14
Kowa Pharmaceuticals America, Inc.1$14
Zyla Life Sciences, Inc.1$11

How this compares

$44,708 in reported general payments places this provider in the 80th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah →

Medicare billing

Part B allowed, 2024
$321,605
Medicare patients
372
Services billed
25,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in American Fork

See the full list for Utah →

Where these figures come from

Is this you, or does something look wrong? →